AMJAD YOUSUF¹, NAJEEB ULLAH KHAN^2,*

Oncology Research, Vol.33, No.4, pp. 851-861, 2025, DOI:10.32604/or.2025.058956 - 19 March 2025

Abstract Breast cancer is a significant global concern, with limited effective treatment options. Therefore, therapies with high efficacy and low complications, unlike the existing chemotherapies, are urgently required. To address this issue, advances have been made in therapies targeting molecular pathways related to the murine double minute 2 proto-oncogene (MDM2)-tumor proteinp53 (TP53) interaction. This review aims to investigate the efficacy of MDM2 inhibition in restoring TP53 activity in breast cancer cells, as evidenced by clinical studies, reviews, and trials. TP53 is a tumor suppressor and MDM2 facilitates proteasomal degradation of TP53. MDM2 and TP53 activity More > Graphic Abstract

Oncology Research Editorial Office

Oncology Research, Vol.33, No.4, pp. 989-989, 2025, DOI:10.32604/or.2024.056912 - 19 March 2025

Abstract This article has no abstract. More >

ZHIZHENG ZHANG^1,#, TAO LI^2,#, YUAN LI³, XI WANG⁴, HAO LIU⁵, XINYU SHEN⁵, ANN XU⁶, TIANSONG XIA^1,*, BO XU^7,*

Oncology Research, Vol.33, No.4, pp. 811-819, 2025, DOI:10.32604/or.2024.050505 - 19 March 2025

Abstract Background: Breast cancer is a prevalent malignant tumor affecting females, with treatment options including surgery, radiotherapy, chemotherapy, and endocrine therapy. Methods: This review synthesizes existing literature on breast cancer stem cells and their applications in breast cancer treatment. PubMed, Web of Science, and other relevant databases were systematically searched using keywords such as “breast cancer stem cells,” “immunotherapy,” “gene therapy,” and “cell therapy.” Studies published in English were included, and their findings were analyzed to provide insights into the characteristics and therapeutic potential of breast cancer stem cells. Results: Breast cancer stem cells exhibit unique properties More >

Rifat Sarker Aoyon¹, Ismail Hossain², M. Abdullah-Al-Wadud³, Jia Uddin^4,*

CMES-Computer Modeling in Engineering & Sciences, Vol.142, No.3, pp. 2617-2640, 2025, DOI:10.32604/cmes.2025.060917 - 03 March 2025

Abstract This research introduces a unique approach to segmenting breast cancer images using a U-Net-based architecture. However, the computational demand for image processing is very high. Therefore, we have conducted this research to build a system that enables image segmentation training with low-power machines. To accomplish this, all data are divided into several segments, each being trained separately. In the case of prediction, the initial output is predicted from each trained model for an input, where the ultimate output is selected based on the pixel-wise majority voting of the expected outputs, which also ensures data privacy.… More >

Oncology Research Editorial Office

Oncology Research, Vol.33, No.3, pp. 739-739, 2025, DOI:10.32604/or.2024.056911 - 28 February 2025

Abstract This article has no abstract. More >

HUAFANG HUANG^1,2,#, GUILIN WANG^3,#, DONGYUN ZENG^4,5, LUZ ANGELA TORRES-DE LA ROCHE², RUI ZHUO^1,2, RUDY LEON DE WILDE², WANWAN WANG⁶, ULF D. KAHLERT^7,*, WENJIE SHI^7,*

Oncology Research, Vol.33, No.3, pp. 631-640, 2025, DOI:10.32604/or.2024.054642 - 28 February 2025

Abstract Background: Neoadjuvant chemotherapy (NAC) significantly enhances clinical outcomes in patients with triple-negative breast cancer (TNBC); however, chemoresistance frequently results in treatment failure. Consequently, understanding the mechanisms underlying resistance and accurately predicting this phenomenon are crucial for improving treatment efficacy. Methods: Ultrasound images from 62 patients, taken before and after neoadjuvant therapy, were collected. Mitochondrial-related genes were extracted from a public database. Ultrasound features associated with NAC resistance were identified and correlated with significant mitochondrial-related genes. Subsequently, a prognostic model was developed and evaluated using the GSE58812 dataset. We also assessed this model alongside clinical factors… More >

RAZIEH MOMEN-MESGIN¹, JAFAR REZAIE^2,*, VAHID NEJATI¹, PEYMAN NAJAFI MOGHADAM³

Oncology Research, Vol.33, No.3, pp. 665-674, 2025, DOI:10.32604/or.2024.054487 - 28 February 2025

Abstract Objectives: Due to systematic side effects, there is a growing interest in nanoparticle formulation of anticancer drugs. Here, we aimed to synthesize poly (styrene-alt-maleic anhydride) cross-linked by melamine (PSMA/Me) and coated with magnetite nanoparticles (MNPs) PSMA/Me/Fe₃O₄. In addition, we aimed to load paclitaxel (PTX) into PSMA/Me/Fe₃O₄ for drug delivery and anticancer investigations. Methods: Novel PSMA/Me was synthesized via free radical copolymerization, coated with Fe₃O₄, and then used as a transporter for PTX delivery. Fabricated copolymer was characterized using SEM, TGA, and XRD techniques. Drug release rate and loading efficiency were investigated. Human ovarian cancer cells (Skov-3) and… More >

SHUANG CHEN^1,2,#, XUEMEI DENG^2,#, XINGTING HE², KEWEI XIANG², GUIHONG CHEN², HONGRU YANG^2,*

Oncology Research, Vol.33, No.3, pp. 687-694, 2025, DOI:10.32604/or.2024.052133 - 28 February 2025

Abstract Background: Previous experiments have demonstrated that hypofractionated radiation therapy (HFRT), low-dose radiation therapy (LDRT), and combined anti-programmed cell death protein 1 (αPD-1) can enhance the abscopal effect. Combined with the phenomenon of low prognosis in patients with breast cancer lung metastasis, our study establishes a mouse model and changes the irradiation regimen of LDRT to explore its preventive effect on breast cancer lung metastasis. Methods: The breast cancer subcutaneous graft tumor model was developed. Two-lung prophylactic LDRT was performed prior to the onset of lung metastases, in combination with HFRT (8 Gy, 3f), and αPD-1… More >

LI SUN^1,#, SHICHAO ZHUO^2,#, XIAOXIN LI², HUSHENG KONG³, WEIWEI DU³, CHONG ZHOU⁴, JUNXING HUANG^1,*

Oncology Research, Vol.33, No.3, pp. 641-651, 2025, DOI:10.32604/or.2024.050057 - 28 February 2025

Abstract Background: Cisplatin (DDP) has been used in the treatment of various human cancers. However, DDP alone lacks efficacy in treating triple-negative breast cancer (TNBC), and its clinical application is often hampered by side effects. Astragalus polysaccharide (APS) is one of the active components extracted from Astragalus membranaceus and has gained attention for its various biological properties. This research is aimed to evaluate the effectiveness of a combination of APS and DDP on TNBC and explore the potential mechanisms. Methods: The efficacy and mechanisms of single or combined treatment were evaluated using Cell Counting Kit-8 (CCK8) assay, Annexin… More >

EDMUND CHEUNG SO^1,2,#, LOUIS W. C. CHOW^3,#, CHIN-MIN CHUANG⁴, CING YU CHEN^5,6, CHENG-HSUN WU⁷, LIAN-RU SHIAO⁸, TING-TSZ OU⁹, KAR-LOK WONG¹⁰, YUK-MAN LEUNG^8,*, YI-PING HUANG^8,*

Oncology Research, Vol.33, No.2, pp. 397-406, 2025, DOI:10.32604/or.2024.052743 - 16 January 2025

Abstract Objectives: Mitochondrial Ca²⁺ uniporter (MCU) provides a Ca²⁺ influx pathway from the cytosol into the mitochondrial matrix and a moderate mitochondrial Ca²⁺ rise stimulates ATP production and cell growth. MCU is highly expressed in various cancer cells including breast cancer cells, thereby increasing the capacity of mitochondrial Ca²⁺ uptake, ATP production, and cancer cell proliferation. The objective of this study was to examine MCU inhibition as an anti-cancer mechanism. Methods: The effects of MCU-i4, a newly developed MCU inhibitor, on cell viability, apoptosis, cytosolic Ca²⁺, mitochondrial Ca²⁺ and potential, glycolytic rate, generation of ATP, and reactive oxygen species,… More >